Innovent Biologics Appoints Dr. Stanley Sun as New Director of BD & Licensing

Recently, Sun Hongyuan (Stanley) Dr. officially announced his new appointment via a professional social networking platform, formally joining Innovent Biologics asBDWith the Authorized Director (Director of BD & Licensing) position.

Public records indicate that Sun Hongyuan holds the Chartered Financial Analyst (CFA) qualifications, with years of in-depth experience in business development and licensing transactions in the biopharmaceutical industry, since2023Year5In June, officially joined Legend Biotech as Associate Director of Business Development and Licensing, primarily responsible for executing collaborations related to the in-licensing of cell therapy pipeline assets. Leveraging a professional background in cell biology, precisely matched business negotiations for out-licensing and pipeline in-licensing within the cell therapy sector.

Prior to joining Legend Biotech, he had a complete biotechnology enterpriseBDComprehensive end-to-end professional experience, previously at Harbour BioMed (2021.10-2023.5) Held positions as Senior Manager and Deputy Director of Business Development and Licensing, comprehensively managing core business matters including pipeline asset licensing and corporate strategic partnership development; previously served at WuXi Biologics (2019.8-2021.10）Senior Manager, Business Development & Licensing, specializing in the advancement of out-licensing projects for biological drugs; in the early stage of his career, he was at Xiantong Capital (2017.6-2019.8) Served as an Investment Manager, focusing on equity investment analysis of biopharmaceutical startups, and developed a dual-dimensional industry perspective spanning industrial business development and primary market investments.